Griffith University is a leader in drug discovery in Australia with a strong focus on infectious diseases. The University's top chemists, biologists and health-care scientists are tackling cross-disciplinary solutions to a wide range of diseases.
Griffith's Institute for Glycomics leads international research in the new science of carbohydrates-based drug discovery. In collaboration with Hong Kong University - Pasteur Research Centre, the Institute has recently developed a new method to study the influenza virus.
Griffith's Griffith Institute for Drug Discovery is home to Compounds Australia, Australia's only integrated compound management and logistics facility, and the NatureBank, a unique collection of some 60,000 samples derived from plants and marine invertebrates. It was developed over 14 years as part of a $100 million investment from AstraZeneca, representing one of the most successful private-public partnerships in the country.
GRIDD researchers have identified a unique chemical structure from a natural marine organism that specifically targets and kills the malaria parasite. The project was named 2007 Project of the Year by the Geneva-based Medicines for Malaria Venture in May 2008, and is now being moved rapidly forward in the drug development pathway.
GRIDD is also home to the Queensland-based node of the $148 million Cancer Therapeutics Cooperative Research Centre.
Genomics researchers at the Griffith Health Institute have identified a number of gene variants associated with migraine, breast and skin cancer and have patented vaccine antigens and DNA diagnostic tests.